Abstract
A 45-year-old woman was admitted to our hospital complaining of a mass in her left breast. She had previously been diagnosed with myelodysplastic syndrome (MDS), a type of refractory anemia, based on bone marrow findings and chromosome analysis. She received a preoperative transfusion of fresh packed platelets and a recombinant human granulocyte colony-stimulating factor (rhG-CSF) injection. Left partial mastectomy and axillary lymph nodes dissection were performed to treat early breast cancer. Postoperatively, prophylactic radiotherapy of the residual breast and administration of medroxyprogesterone acetate (MPA) were performed because the tumor tissue was positive for progesterone receptors. She has remained clinically stable, with no evidence of recurrence, for more than three years to date. We report a rare case of breast cancer with MDS, treated with breast-conserving therapy. The strategy of pre- or postoperative platelet transfusion, rhG-CSF injections, and hormonal therapy (AAPA) appears to be suitable treatment for progesterone receptor (PgR)-positive breast cancer patients with AADS.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- MDS:
-
Myelodysplastic syndrome
- ER:
-
Estrogen receptor
- PgR:
-
Progesterone receptor
- rhG-CSF:
-
Recombinant human granulocyte colony-stimulating factor
- MPA:
-
Medroxyprogesterone acetate
References
Bennett JM, Catovsky D, Daniel MT,et al: Proposals for the classification of the myelodysplastic syndromes.BrJ Haematol 51:189–199, 1982.
Yoshida Y, Stephenson J, Mufti GJ: Myelodysplastic syndromes; From morphology to molecular biology, Part I; Classification, natural history and cell biology of myelodysplasia.Int J Hematol 57:87–97, 1993.
Yoshida Y, Oguma S, Uchino H,et al: Clinical features and prognosis of refractory myelodysplastic anemias.Nippon Ketsueki Gakkai Zasshi (Ada Haematol Jpn) 50:3745, 1987 (in Japanese with English abstract).
Gunz FW, Angus HS: Leukemia and cancer in the same patient.Cancer 18:145–159, 1986.
Heim S: Cytogenetic findings in primary and secondary MDS.Leuk Res 16:43–46, 1992.
Bonin SR, Lanciano RM, Smith MR,et al: Treatment- related myelodysplastic syndrome following abdomino-pelvic radiotherapy for endometrial cancer.Gynecol Oncol 57:430–432, 1995.
Clark RE, Payne HE, Jacobs A,et al: Primary myelodysplasic syndrome and cancer.Br Med J Clin Res 294:937–938, 1987.
Cavanna L, Vallisa D, Di-Stasi M,et al: Acute myelocytic leukemia and chronic myelomonocytic leukemia simultaneously with resectable breast cancer; A report of two cases.Tumori 78:356–358, 1992.
Niitsu N, Umeda M: Double cancer in elderly patients with hématologic malignancies.Nippon Ronen Igakkai Zasshi 33:269–272, 1996 (in Japanese with English abstract).
Travis LB, Weeks J, Curtis RE,et al: Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin’s lymphoma.J Clin Oncol 14:565–571, 1996.
Sanz GF, Sanz MA: Prognostic factors in myelodysplastic syndromes.Leuk Res 16:77–86, 1992.
Amadori D, Frassineti GL, Flamini E,et at Clinical and laboratory evaluation of the myeloprotective effect of medroxyprogesterone acetate in head and neck cancer.Eur J Cancer 28:1331–1334, 1992.
Fink M: Possible effect of medroxyprogesterone acetate (MPA) in lymphoid blast crisis of chronic myelogenous leukemia.Ann Hematol 68:89–90, 1994.
Stadtmauer EA, Cassileth PA, Edelstein M,et at Danasol treatment of myelodysplastic syndromes.Br J Haematol 77:502–508, 1991.
Buzaid AC, Garewal HS, Lippman SM,et at Danasol in the treatment of myelodysplastic syndromes.EurJ Haematol 39:346–348, 1987.
Author information
Authors and Affiliations
About this article
Cite this article
Kataoka, T., Kadoya, T., Sugi, K. et al. Early breast cancer following treatment of myelodysplastic syndrome: Report of a case. Breast Cancer 5, 183–186 (1998). https://doi.org/10.1007/BF02966693
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02966693